Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2019)

First Author: Yiu ZZN
Attributed to:  MICA: The Newcastle Proximity Laboratory funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bjd.17036

PubMed Identifier: 30070708

Publication URI: http://europepmc.org/abstract/MED/30070708

Type: Journal Article/Review

Volume: 180

Parent Publication: The British journal of dermatology

Issue: 2

ISSN: 0007-0963